BACKGROUND: Chronic hepatitis C (HCV) infected patients with coexisting mental health and/or substance abuse issues face significant barriers to treatment and are often deferred. This paper sought to highlight critical pre-treatment strategies and provide tangible resources for HCV clinicians to facilitate preparation and successful treatment of these patients. METHODS: Guided by the clinical experience of our liver center, a large, tertiary academic medical center, and informed by the extant literature, we summarize pre-treatment strategies and specific resources and recommendations for HCV providers. RESULTS: Four key pre-treatment strategies include: 1) screening for mental health/substance abuse issues using brief, reliable and validated instruments; 2) locating and establishing collaborative care with mental health and substance abuse specialists; 3) using a motivational interviewing communication style; and 4) addressing adherence-related issues. CONCLUSIONS: HCV clinicians are in a unique position to prepare patients with coexisting mental health and/or substance abuse issues for antiviral therapy.
BACKGROUND:Chronic hepatitis C (HCV) infectedpatients with coexisting mental health and/or substance abuse issues face significant barriers to treatment and are often deferred. This paper sought to highlight critical pre-treatment strategies and provide tangible resources for HCV clinicians to facilitate preparation and successful treatment of these patients. METHODS: Guided by the clinical experience of our liver center, a large, tertiary academic medical center, and informed by the extant literature, we summarize pre-treatment strategies and specific resources and recommendations for HCV providers. RESULTS: Four key pre-treatment strategies include: 1) screening for mental health/substance abuse issues using brief, reliable and validated instruments; 2) locating and establishing collaborative care with mental health and substance abuse specialists; 3) using a motivational interviewing communication style; and 4) addressing adherence-related issues. CONCLUSIONS:HCV clinicians are in a unique position to prepare patients with coexisting mental health and/or substance abuse issues for antiviral therapy.
Authors: Astrid Knott; Eric Dieperink; Mark L Willenbring; Sara Heit; Janet M Durfee; Mary Wingert; James R Johnson; Paul Thuras; Samuel B Ho Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: S Nassir Ghaemi; Christopher J Miller; Douglas A Berv; Jeffry Klugman; Klara J Rosenquist; Ronald W Pies Journal: J Affect Disord Date: 2005-02 Impact factor: 4.839
Authors: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Jason Grebely; Krista Genoway; Milan Khara; Fiona Duncan; Mark Viljoen; Doug Elliott; Jesse D Raffa; Stanley DeVlaming; Brian Conway Journal: Int J Drug Policy Date: 2007-04-27
Authors: Patricia C Valery; Elizabeth Powell; Neta Moses; Michael L Volk; Steven M McPhail; Paul J Clark; Jennifer Martin Journal: BMJ Open Date: 2015-04-08 Impact factor: 2.692
Authors: C Torti; M Zazzi; L Abenavoli; F Trapasso; F Cesario; D Corigliano; L Cosco; C Costa; R L Curia; M De Rosa; G Foti; C Giraldi; R Leone; M C Liberto; D Lucchino; N Marascio; R Masciari; G Matera; V Pisani; N Serrao; L Surace; E Zicca; F Castelli; M Ciccozzi; M Puoti; A Focà Journal: BMC Infect Dis Date: 2012-11-12 Impact factor: 3.090